# US 2024/0182480 A1 · 5-ht2a and/or 5-ht2c receptor agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0182480 A1
- Document ID: US20240182480A1
- Status: Published application
- Kind: A1
- Application number: 18/501,238
- Filed: 2023-11-03
- Published: 2024-06-06
- Earliest claimed: 2021-05-05
- Assignees: Diamond Therapeutics Inc.
- Applicants: Diamond Therapeutics Inc.
- Inventors: Methvin ISAAC
- Web page: https://patentgrep.com/patent/US20240182480A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/02: for peripheral neuropathies
- A61P 25/24: Antidepressants
- C07D 471/14: Ortho-condensed systems
- C07D 487/14: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are heterocyclic compounds, processes for their preparation, compositions comprising said compounds, and use in therapy. More particularly, the present disclosure relates to fluorinated and/or deuterated analog useful in the treatment of diseases, disorders or conditions treatable by modulating the 5-HT2 receptor subtypes.

## Claims

### Claim at position 1

1-153. (canceled)

### Claim 154

A compound, or pharmaceutically acceptable salt or solvate thereof, having the structure of Formula (I):
wherein
R1, R2 and R3 are each independently selected from H and C1-C6 optionally substituted alkyl; and
ring A is an optionally substituted heteroaryl ring selected from
wherein
* represents the points of attachment;
R4 and R5 are independently selected from H, halo, CN, C1-4alkyl, C1-4haloalkyl, OC1-4alkyl, OC1-4haloalkyl, O(optionally substituted C3-10 carbocycle),
O(optionally substituted C3-10 aryl), and N(R8R9);
R6 and R7 are independently selected from H and C1-C6 optionally substituted alkyl; and
R8 and R9 are joined to form, together with the atom therebetween, a C3-12heterocycloalkyl, optionally comprising one additional heteromoiety selected from N(R10), O, S, S(O) and SO2, and optionally substituted with one or more substituents selected from halo, OH, C1-6alkyl, C3-6cycloalkyl, aryl, C5-6heteroaryl, C3-6 heterocycloalkyl, C1-6 alkyleneC3-6cycloalkyl, C1-6alkylenearyl, C1-6alkyleneC5-6heteroaryl, C1-6alkyleneC3-6heterocycloalkyl, C(O)C1-6alkyl, OC1-6alkyl, OC1-6alkyleneOC1-6alkyl, C(O)NH2, C(O)NH(C1-6alkyl), C(O)N(C1-6alkyl)(C1-6alkyl), NHC(O)C1-6alkyl, N(C1-6alkyl)C(O)C1-6alkyl, NH2, NH(C1-6alkyl), N(C1-6alkyl)(C1-6alkyl), SC1-6alkyl, S(O)C1-6alkyl, and SO2C1-6alkyl, wherein
R10 is selected from hydrogen, C1-6alkyl, C3-6cycloalkyl, aryl, C5-6heteroaryl, C3-6 heterocycloalkyl, C1-6 alkyleneC3-6cycloalkyl, C1-6alkylenearyl, C1-6alkyleneC5-6heteroaryl, C1-6alkyleneC3-6heterocycloalkyl, C(O)C1-6alkyl, C(O)NH2, C(O)NH(C1-6alkyl), C(O)N(C1-6alkyl)(C1-6alkyl), S(O)C1-6alkyl, and SO2C1-6alkyl; and
all alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups of the optional substituents on the C3-12heterocycloalkyl formed by R8 and R9 are optionally substituted with one or more substituents selected from halo, C1-6alkyl, OC1-6alkyl, C1-6haloalkyl, and OC1-6haloalkyl.

### Claim 155 (depends on 154)

The compound, salt, or solvate of claim 154, wherein ring A is
R1 is H, and R2 is C1-6 alkyl.

### Claim 156 (depends on 155)

The compound, salt, or solvate of claim 155, wherein ring A is
R1 is H, and R2 is methyl.

### Claim 157 (depends on 154)

The compound, salt, or solvate of claim 154, wherein ring A is
and R3 is H.

### Claim 158 (depends on 154)

The compound, salt, or solvate of claim 154, wherein R10 is selected from hydrogen, and C1-6alkyl.

### Claim 159 (depends on 154)

The compound, salt, or solvate of claim 154, wherein the heterocycle formed by R8 and R9 is selected from

### Claim 160 (depends on 154)

The compound, salt, or solvate of claim 154, wherein R8 and R9 are methyl.

### Claim 161 (depends on 154)

The compound, salt, or solvate of claim 154, wherein
R1 and R2 are H;
R3 is selected from H and C1-C6 optionally substituted alkyl;
ring A is
R4 and R5 are each independently selected from H, C1-4haloalkyl, OC1-4alkyl, OC1-4haloalkyl, O(optionally substituted C3-10 carbocycle), O(optionally substituted C3-10 aryl), and N(R8R9);
R8 and R9 are joined to form, together with the atom therebetween, a C3-12heterocycloalkyl, and optionally substituted with one or more substituents selected from halo, OH, NO2, C1-6alkyl, C3-6cycloalkyl, aryl, C5-6heteroaryl, C3-6 heterocycloalkyl, C1-6alkyleneC3-6cycloalkyl, C1-6alkylenearyl, C1-6alkyleneC5-6heteroaryl, C1-6alkyleneC3-6heterocycloalkyl, C(O)C1-6alkyl, OC1-6alkyl, OC1-6alkyleneOC1-6alkyl, C(O)NH2, C(O)NH(C1-6alkyl), C(O)N(C1-6alkyl)(C1-6alkyl), NHC(O)C1-6alkyl, N(C1-6alkyl)C(O)C1-6alkyl, NH2, NH(C1-6alkyl), N(C1-6alkyl)(C1-6alkyl), SC1-6alkyl, S(O)C1-6alkyl, and SO2C1-6alkyl, wherein
R10 is selected from C1-6alkyl, C3-6cycloalkyl, aryl, C5-6heteroaryl, C3-6 heterocycloalkyl, C1-6 alkyleneC3-6cycloalkyl, C1-6alkylenearyl, C1-6alkyleneC5-6heteroaryl, C1-6alkyleneC3-6heterocycloalkyl, C(O)C1-6alkyl, C(O)NH2, C(O)NH(C1-6alkyl), C(O)N(C1-6alkyl)(C1-6alkyl), S(O)C1-6alkyl, and SO2C1-6alkyl.

### Claim 162 (depends on 159)

The compound, salt, or solvate of claim 159, wherein ring A is
R1 is H, and R2 is C1-6 alkyl.

### Claim 163 (depends on 162)

The compound, salt, or solvate of claim 162, wherein ring A is
R1 is H, and R2 is methyl.

### Claim 164 (depends on 154)

The compound, salt, or solvate of claim 154, wherein R3 is H.

### Claim 165 (depends on 164)

The compound, salt, or solvate of claim 164, wherein ring A is
and R3 is H.

### Claim 166 (depends on 165)

The compound, salt, or solvate of claim 165, wherein the heterocycle formed by R8 and R9 is selected from

### Claim 167 (depends on 165)

The compound, salt, or solvate of claim 165, wherein R8 and R9 are methyl.

### Claim 168 (depends on 166)

The compound of claim 166, or pharmaceutically acceptable salt or solvate thereof, having the structure:

### Claim 169 (depends on 166)

The compound of claim 166, or pharmaceutically acceptable salt or solvate thereof, having the structure:

### Claim 170 (depends on 166)

The compound of claim 166, or pharmaceutically acceptable salt or solvate thereof, having the structure:

### Claim 171 (depends on 166)

The compound of claim 166, or pharmaceutically acceptable salt or solvate thereof, having the structure:

### Claim 172

A compound, or pharmaceutically acceptable salt or solvate thereof, as provided in Table 1.

### Claim 173

A compound, or pharmaceutically acceptable salt or solvate thereof, selected from
